Orasis Pharmaceuticals snags $30M to see its presbyopia treatment through to PhIII
Orasis Pharmaceuticals is one of several biotechs developing miotic-based eye drops as a potential alternative to reading glasses — one drop, and no more squinting at text messages. With the help of a $30 million Series C, the Israel-based company has its sights set on Phase III.
“Reading glasses are inconvenient, they are not aesthetically pleasing for many people, and then finally, they are also one of the very first signs of aging,” said CEO Elad Kedar, who joined Orasis in 2015 shortly after the company was founded.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.